Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Claritas Announces Letter of Intent to Acquire Exclusive Worldwide Rights to Develop R-107 for PAH
Claritas Pharmaceuticals, Inc.April 14, 2021 GMT
SAN FRANCISCO and TORONTO, April 14, 2021 (GLOBE NEWSWIRE) Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the “Company” or “Claritas”) today announced that it has entered into a binding Letter of Intent (the “LOI”) with Salzman Group, Inc. (a Delaware corporation), Salzman Group, Ltd. (an Israeli corporation), and Salzman Group Pty. Ltd. (an Australian corporation), (collectively, the “Salzman Group”), under which Salzman Group will grant to Claritas an exclusive, worldwide license to develop and commercialize R-107 for the treatment of pulmonary arterial hypertension (“PAH”). The Company expects that definitive agreements will be executed by May 15, 2021. Closing of the transaction is subject to rece